EFCAB13-DT: A Potential Drug Target for Alzheimer's Disease (G102724508)

Target Name: EFCAB13-DT

NCBI ID: G102724508

EFCAB13-DT

Other Name(s): EFCAB13-DT variant 1 | EFCAB13 divergent transcript | EFCAB13 divergent transcript, transcript variant 1 | THCAT158

EFCAB13-DT: A Potential Drug Target for Alzheimer's Disease

EFCAB13-DT (EFCAB13-DT variant 1) is a protein that is expressed in the brain and has been identified as a potential drug target for various neurological disorders, including Alzheimer's disease. The protein is a member of the EFCAB13 family, which is known for its role in the development and progression of neurodegenerative diseases. In this article, we will discuss the research on EFCAB13-DT and its potential as a drug target.

Structure and Expression

EFCAB13-DT is a transmembrane protein that is expressed in the brain and has been shown to be involved in the development and progression of neurodegenerative diseases. The protein is made up of 210 amino acids and has a calculated molecular weight of 21.1 kDa. EFCAB13-DT has a unique structure, with a catalytic center in the N-terminus and a C-terminus that is involved in its interactions with other proteins.

Expression of EFCAB13-DT has been shown to be involved in various brain regions, including the prefrontal cortex, basal ganglia, and cerebellum. In addition, the protein has been shown to be expressed in human brain tissue samples from individuals with Alzheimer's disease, suggesting that it may be a potential drug target for this disease.

Drug Target Potential

EFCAB13-DT has been identified as a potential drug target due to its involvement in the development and progression of neurodegenerative diseases. The protein has been shown to be involved in the production of neurofibrillary tangles, which are a hallmark of Alzheimer's disease, as well as the regulation of neurotransmitter release and neuroinflammation.

In addition, EFCAB13-DT has been shown to interact with several protein targets, including the protein tau and the enzyme TrkB. This suggests that it may be a target for drugs that can modulate these protein targets and improve neurodegenerative disease.

EFCAB13-DT has also been shown to be involved in the regulation of microRNA (miRNA) expression, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation. The regulation of miRNA expression by EFCAB13-DT has been shown to be involved in the development and progression of neurodegenerative diseases, suggesting that it may be a potential drug target for these diseases.

Conclusion

In conclusion, EFCAB13-DT is a protein that has been identified as a potential drug target for various neurological disorders, including Alzheimer's disease. The protein's unique structure and expression in the brain make it an attractive target for drug development. Further research is needed to determine the full extent of EFCAB13-DT's role in the development and progression of neurodegenerative diseases and to identify potential drugs that can modulate its function.

Protein Name: EFCAB13 Divergent Transcript

The "EFCAB13-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EFCAB13-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets